Study title:
Multicenter, Phase II, open-label study of
the efficacy, safety, acceptability, and
pharmacokinetics of telithromycin, after
repeated oral administration of either of
two doses, once daily, for 5 days or 7 to
10 days, in the treatment of respiratory
tracts infections in children of 6 months to
12 years
Type of medicine: Centrally authorised medicines
|
Therapeutic area: Bacterial Infections and Mycoses
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: telithromycin |
ATC code: J01FA15 |
Document link:
|
Document date:
|
Study number: HMR 3647B/2001 |
EudraCT number:
|
Scope of study: CLINICAL |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|